The first patient has been treated under the controversial 'right to try' law
A patient diagnosed with an aggressive form of brain cancer became the first person in the US to access an experimental treatment under Right to Try. Signed into law by President Donald Trump in May 2018, it has been touted as a new way to help people with terminal illnesses and few options, although until now, no patients had ever used it.
ERC-USA and the University of California, Irvine initiated treatment with the company’s investigational compound ERC-1671 — known as Gliovac in Europe — and which is in Phase 2 clinical trials in the US. The patient’s treatment with ERC-1671 began at the university in late November 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.